Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) and Kodiak Sciences Inc. (NASDAQ:KOD) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catabasis Pharmaceuticals Inc.||N/A||0.00||25.87M||-80.26||0.00|
|Kodiak Sciences Inc.||N/A||0.00||41.44M||-1.07||0.00|
Table 1 demonstrates Catabasis Pharmaceuticals Inc. and Kodiak Sciences Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 provides Catabasis Pharmaceuticals Inc. and Kodiak Sciences Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Catabasis Pharmaceuticals Inc.||0.00%||-91.2%||-76.8%|
|Kodiak Sciences Inc.||0.00%||0%||0%|
Catabasis Pharmaceuticals Inc. has a Current Ratio of 10.8 and a Quick Ratio of 10.8. Competitively, Kodiak Sciences Inc.’s Current Ratio is 2.3 and has 2.3 Quick Ratio. Catabasis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Kodiak Sciences Inc.
Recommendations and Ratings for Catabasis Pharmaceuticals Inc. and Kodiak Sciences Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Catabasis Pharmaceuticals Inc.||0||0||1||3.00|
|Kodiak Sciences Inc.||0||0||1||3.00|
$46 is Catabasis Pharmaceuticals Inc.’s consensus price target while its potential upside is 512.52%. On the other hand, Kodiak Sciences Inc.’s potential upside is 200.40% and its consensus price target is $22.5. The results provided earlier shows that Catabasis Pharmaceuticals Inc. appears more favorable than Kodiak Sciences Inc., based on analyst view.
Institutional and Insider Ownership
Catabasis Pharmaceuticals Inc. and Kodiak Sciences Inc. has shares held by institutional investors as follows: 24.1% and 48.2%. Insiders held 1.93% of Catabasis Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 11.8% of Kodiak Sciences Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Catabasis Pharmaceuticals Inc.||0.2%||-21.98%||-20.76%||-35.96%||-75.03%||13.73%|
|Kodiak Sciences Inc.||1.45%||-8.98%||-24.19%||0%||0%||-1.55%|
For the past year Catabasis Pharmaceuticals Inc. has 13.73% stronger performance while Kodiak Sciences Inc. has -1.55% weaker performance.
Catabasis Pharmaceuticals Inc. beats on 4 of the 7 factors Kodiak Sciences Inc.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich’s ataxia and amyotrophic lateral sclerosis. The company has preclinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.